Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. (Q53004947)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Maya Koren-Michowitz

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

object named as

Raz Somech

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Avichai Shimoni

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Yulia Volchek

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Nira Varda-Bloom

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Noga Shem-Tov

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ronit Yerushalmi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Arnon Nagler

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

11 November 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

121

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

863-871

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia pos

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

21 January 2018

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29141

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29141

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25387866%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53004947&oldid=1425039898"